Since the birth of the discipline of Pharmacology, one of the primary goals of pharmacologists has been to reveal the messages contained within drug molecules that influence system physiology. For many years it was thought that messages contained within drugs were delivered by two drug properties: affinity (the capacity to bind) and intrinsic efficacy (the capacity to change a receptor's behavior toward it's host). Affinity was responsible for a drug's selectivity (which receptors a drug could influence). Intrinsic efficacy conveyed a drug's strength by the magnitude (null, weak {partial}, strong) and direction (negative or positive) of the receptor stimulus it produced upon binding.
Intrinsic efficacy was originally proposed by Furchgott (1966) to reflect the capacity of a drug to produce a receptor stimulus (Stephenson, 1956 ). This receptor stimulus was delivered to the signal transduction apparatus of a cell, resulting in a cellular response, the magnitude of which was dependent upon the size of the total stimulus (the product of the receptor stimulus and the number of receptors in the cell) and the efficiency of stimulus-response coupling (signal transduction). In Furchgott's framework, intrinsic efficacy was a drug property, unique for each drug-receptor pair, that was independent of the signaling system coupled to a receptor. Although intrinsic efficacy could not be measured directly, relative efficacy measures, which normalize for differences in signal transduction efficiency, could be used to assess the relative magnitude of the stimulus a drug elicits. Thus, intrinsic efficacy was of value for drug discovery since it could be used to predict the relative magnitude of a response to a drug in any cell/tissue if the drug's relative efficacy in another tissue was known.
In more contemporary models of receptor function, intrinsic efficacy and receptor stimulus can be related to the capacity of a drug to promote a change in receptor conformation This article has not been copyedited and formatted. The final version may differ from this version. which increases its ability to interact with cellular signaling molecules, such as G proteins. For receptors coupled to multiple signaling pathways within a cell, a single receptor stimulus would be delivered to each of the signaling pathways, each of which could have different transduction efficiencies to convert the stimulus into a response. However, because there is a single stimulus, measurement of drug relative efficacy (which obviates response-dependent differences in signaling efficiency) must be the same for each response coupled to a receptor.
In recent years, data have accumulated which challenge this view of intrinsic efficacy.
Several studies have reported that agonist relative efficacy is different when different responses are measured, even within the same cell (for reviews see, Clarke and Bond, 1998; Kenakin, 2003a; Kenakin, 2003b) . Such studies have initiated a re-definition of the concept of intrinsic efficacy such that ligands can produce multiple stimuli (have multiple intrinsic efficacies) upon interaction with a receptor and can differentially regulate each of multiple signaling pathways coupled to a receptor. This ligand behavior has been termed "agonist-directed trafficking of receptor stimulus", "functional selectivity", "stimulus trafficking", and "biased agonism". The underlying mechanism for this is proposed to be based upon the capacity of ligands to promote the unique, ligand-selective receptor conformations which have differential efficacy to regulate signal transduction pathways.
Receptors, like all proteins, spontaneously adopt a variety of conformations, some of which may be able to regulate signaling pathways and are thus said to be "active" and given the symbols, R*, R**, R**, etc., with R denoting an inactive receptor. When a ligand is added, it will bind to these receptor conformations according to the relative affinity of the ligand for each conformation and thus will enrich certain receptor conformations and deplete others. A different This article has not been copyedited and formatted. The final version may differ from this version. ligand, with different relative affinities, will stabilize a different spectrum of receptor conformations. Kenakin has coined the term "conformational cafeteria" to describe the process whereby ligands enter receptor space and selectively stabilize ("choose") certain conformations for which they have highest affinity (Kenakin, 2002; Kenakin and Onaran, 2002) . As a consequence, ligand-selective receptor conformations may mediate ligand-selective signaling via a single receptor subtype.
In this issue of Molecular Pharmacology, Mukhopadhyay and Howlett (2005) provide evidence of ligand-selective conformations of the CB1 cannabinoid receptor. Using CHAPS solubilized extracts of membranes prepared from N18TG2 cells, which naturally express the CB1 receptor, Mukhopadhyay and Howlett examined the ability of three structurally different classes of CB1 ligands, previously characterized as agonists, to interact with specific G protein subtypes (Gα i 1, Gα i 2, and Gα i 3). In the absence of ligands, a large fraction of the solubilized Gα i proteins co-immunoprecipitated with the CB1 receptor in a pertussis toxin-and GTPγS-sensitive manner, confirming earlier reports that the CB1 receptor can spontaneously couple to and activate G proteins (constitutive activity) in recombinant and native cell systems (for a review see, Pertwee, 2005) . In the absence of GTPγS, the aminoalkylindole WIN55212-2 (WIN), the cannabinoid desacetyllevonantradol (DALN), or the eicosanoid (R)-methanandamide promoted a mixture of CB1 receptor-Gα i complexes and free receptors differentially depending upon the Gα i subtype. These data suggest that there is differential G protein subtype coupling to the CB1 receptor when occupied by different ligands.
The effect of GTPγS to destabilize receptor-G protein complexes was examined in the presence of the three different ligands. As expected, incubation with GTPγS reduced (85-100%) This activation by the calcium-sensing receptor, stimulated with 4 mM calcium, was mediated by Gα i 2 but not by Gα i 1 or Gα i 3. These data suggest that even though they are highly homologous, the different Gα i subtypes may subserve different physiological functions in cells. Consequently, differential activation/inactivation of these G protein subtypes by cannabinoid ligands may lead to different physiological effects.
In addition to differential G protein coupling and signaling (Berg et al., 2001; This article has not been copyedited and formatted. The final version may differ from this version. Bonhaus et al., 1998; Cordeaux et al., 2000; Kurrasch-Orbaugh et al., 2003; MacKinnon et al., 2001; Mailman and Gay, 2004; Mottola et al., 2002) , there have been a variety of other approaches which provide evidence for ligand-selective receptor conformations, including ligand-dependent receptor internalization (Hunyady et al., 1994; Roettger et al., 1997; Whistler et al., 1999) , phosphorylation and desensitization (Blake et al., 1997; Chakrabarti et al., 1998; Stout et al., 2002; Thomas et al., 2000) , ligand binding affinity (Liapakis et al., 2004; LopezGimenez et al., 2001) , and kinetics of activation (Krumins and Barber, 1997; Swaminath et al., 2004) . Perhaps the most direct method is through the use of fluorescent receptor tags which are sensitive to changes in receptor conformation. Using fluorescence lifetime spectroscopy, Ghanouni et al. (2001) 
